Alzheimer Disease Clinical Trials in Austin, Texas

8 studies are recruiting for alzheimer disease in Austin, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

   This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.

   Stage

   Phase 2

   Ages

   55 to 90

   Site

   Pinnacle Clinical Research, Austin, Texas

   Locations

   78 in total

   Run by

   Celgene

   See if you can join NCT06808984 on ClinicalTrials.gov

2. A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

   The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.

   Stage

   Phase 3

   Ages

   55 to 90

   Site

   Senior Adults Specialty Research, Austin, Texas

   Locations

   293 in total

   Run by

   Karuna Therapeutics, Inc., a Bristol Myers Squibb company

   See if you can join NCT06585787 on ClinicalTrials.gov

3. A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

   The main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For each participant, the study will last up to 2.5 years and will include 6 visits.

   Stage

   Phase 3

   Ages

   55 and older

   Site

   Senior Adults Specialty Research, Austin, Texas

   Locations

   59 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07602582 on ClinicalTrials.gov

4. Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia

   Difficulties with speech and language are the first and most notable symptoms of primary progressive aphasia (PPA). While there is evidence that demonstrates positive effects of speech-language treatment for individuals with PPA who only speak one language (monolinguals), there is a significant nee…

   Stage

   Not phased

   Ages

   40 and older

   Site

   University of Texas at Austin, Austin, Texas

   Locations

   3 in total

   Run by

   Stephanie Grasso

   See if you can join NCT05741853 on ClinicalTrials.gov

5. Educational Support Group Program for Bilingual and Spanish-speaking Carepartners and People With Progressive Aphasia

   The current study aims to examine the benefits of an education/support group program for individuals with progressive aphasia (caused by various etiologies, diagnoses) and their carepartners. The current study utilizes pre-, post-treatment, and follow-up assessments to measure effects of a psychoed…

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   University of Texas at Austin, Austin, Texas

   Run by

   University of Texas at Austin

   See if you can join NCT06511752 on ClinicalTrials.gov

6. Clinical Trial on Agitation in Alzheimer's Dementia

   The purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administered twice a day on Agitation in patients with mild to severe dementia from Alzheimer's.

   Stage

   Phase 2

   Ages

   60 and older

   Site

   Senior Adults Specialty Research, Austin, Texas

   Locations

   31 in total

   Run by

   IGC Pharma, LLC

   See if you can join NCT05543681 on ClinicalTrials.gov

7. Paper-Based and Smartphone-Based Memory Supports

   Alzheimer's disease and related dementias lead to marked declines in daily functioning, independence, and quality of life. One of the earliest cognitive changes in these conditions is impairment in prospective memory, or the ability to remember future intentions such as taking medications at a give…

   Stage

   Not phased

   Ages

   50 and older

   Site

   UT Health Austin Comprehensive Memory Center, Austin, Texas

   Locations

   3 in total

   Run by

   Baylor University

   See if you can join NCT06444841 on ClinicalTrials.gov

8. Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease

   Nighttime agitation in persons with Alzheimer's disease causes patient suffering, distresses caregivers, and often results in prescriptions for harmful antipsychotics. Effective treatments are lacking because of limited knowledge of the etiology of nighttime agitation. The investigators propose a c…

   Stage

   Phase 4

   Ages

   55 and older

   Site

   The University of Texas at Austin, Austin, Texas

   Run by

   University of Texas at Austin

   See if you can join NCT03082755 on ClinicalTrials.gov